Aditxt (ADTX) Stock Price, News & Analysis

Company Overview

Aditxt, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols. In parallel, Aditxt is advancing a pipeline of peptide-based formulations intended for topical applications such as wound care and surface decontamination. Its research and development activities are conducted at its laboratory facilities in North Brunswick, New Jersey, with additional collaborations in Europe and Latin America under strategic licensing agreements.

Aditxt holds multiple issued and pending patents covering peptide sequences and delivery methods, and the company has established partnerships with academic institutions and contract research organizations to support preclinical and clinical studies. By integrating microbial testing services with the development of proprietary antimicrobial compounds, Aditxt seeks to offer end-to-end solutions that span detection, prevention and treatment of pathogenic microorganisms in diverse settings.

Headquartered in North Brunswick, New Jersey, Aditxt is led by Chief Executive Officer Rami Sinai, who brings experience in biotechnology entrepreneurship and strategic development. The management team combines expertise in peptide chemistry, microbiology and regulatory affairs, positioning the company to advance its technology platforms toward commercialization and to address the global challenge of antimicrobial resistance.

Key Stats

• Today's Range: $0.18 to $0.22
• 50-Day Range: $0.25 to $43.74
• 52-Week Range: $0.18 to $53,451.08
• Volume: 4.15 million shs
• Average Volume: 334,000 shs
• Market Capitalization: $6.44 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Aditxt Stock Analysis - MarketRank™

Aditxt scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Aditxt has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Aditxt has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aditxt is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aditxt is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

27.05% of the float of Aditxt has been sold short.

Short Interest Ratio / Days to Cover

Aditxt has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aditxt has recently increased by 65.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aditxt does not currently pay a dividend.

Dividend Growth

Aditxt does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.50

News Sentiment

Aditxt has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Aditxt this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Aditxt to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $11,132.00 in company stock, which represents 177.5439% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Aditxt insiders have bought 86.13% more of their company's stock than they have sold. Specifically, they have bought $24,057.00 in company stock and sold $12,925.00 in company stock.

Percentage Held by Insiders

0.01% of the stock of Aditxt is held by insiders.

Percentage Held by Institutions

15.54% of the stock of Aditxt is held by institutions.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/27/2026
• Next Earnings (Estimated): 6/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADTX
• CIK: 1726711
• Web: www.aditxt.com
• Phone: 650-870-1200
• Fax: N/A
• Employees: 60
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): ($11,103.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.71 million
• Net Margins: -360,152.50%
• Pretax Margin: -367,584.03%
• Return on Equity: -374.60%
• Return on Assets: -105.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: $14.34 thousand
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1,051.07) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 33,000
• Free Float: 33,000
• Market Cap: $6.30 thousand
• Optionable: No Data
• Beta: 1.08